{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:25:20Z","timestamp":1776702320497,"version":"3.51.2"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Dementia Australia Research Foundation Mid-Career Research Fellowship"},{"DOI":"10.13039\/501100001774","name":"The University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40263-026-01282-z","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:37:50Z","timestamp":1772563070000},"page":"697-708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multiple Adverse Outcomes Associated with Risperidone in People with Dementia: An Individual Participant Data Meta-Analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-7778","authenticated-orcid":false,"given":"Hieu T.","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5712-2337","authenticated-orcid":false,"given":"Edward C. Y.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7550-6837","authenticated-orcid":false,"given":"Christine Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5970-1501","authenticated-orcid":false,"given":"Sarah N.","family":"Hilmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2031-9134","authenticated-orcid":false,"given":"Yun-Hee","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9283-3525","authenticated-orcid":false,"given":"Lee-Fay","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-9278","authenticated-orcid":false,"given":"Tuan A.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2922-8837","authenticated-orcid":false,"given":"Edwin C. K.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"2","key":"1282_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/s2468-2667(21)00249-8","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105\u201325. https:\/\/doi.org\/10.1016\/s2468-2667(21)00249-8.","journal-title":"Lancet Public Health"},{"key":"1282_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.710703","volume":"12","author":"CV Burley","year":"2021","unstructured":"Burley CV, Casey AN, Chenoweth L, Brodaty H. Reconceptualising behavioral and psychological symptoms of dementia: views of people living with dementia and families\/care partners. Front Psychiatry. 2021;12:710703. https:\/\/doi.org\/10.3389\/fpsyt.2021.710703.","journal-title":"Front Psychiatry"},{"key":"1282_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf013","author":"K Anantapong","year":"2025","unstructured":"Anantapong K, Jiraphan A, Aunjitsakul W, Sathaporn K, Werachattawan N, Teetharatkul T, et al. Behavioural and psychological symptoms of people with dementia in acute hospital settings: a systematic review and meta-analysis. Age Ageing. 2025. https:\/\/doi.org\/10.1093\/ageing\/afaf013.","journal-title":"Age Ageing"},{"key":"1282_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00596","volume":"11","author":"I Yunusa","year":"2020","unstructured":"Yunusa I, El Helou ML. The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use. Front Pharmacol. 2020;11:596. https:\/\/doi.org\/10.3389\/fphar.2020.00596.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1282_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40266-025-01220-6","volume":"42","author":"HT Le","year":"2025","unstructured":"Le HT, Lau ECY, Chen W, Lu CY, Nguyen TA, Low LF, et al. Prevalence and risk factors for psychotropic medication use in older adults in Australia: a nationwide data linkage study. Drugs Aging. 2025;42(8):755\u201369. https:\/\/doi.org\/10.1007\/s40266-025-01220-6.","journal-title":"Drugs Aging"},{"issue":"3","key":"1282_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/0706743716673321","volume":"62","author":"J Kirkham","year":"2017","unstructured":"Kirkham J, Sherman C, Velkers C, Maxwell C, Gill S, Rochon P, et al. Antipsychotic use in dementia. Can J Psychiatry. 2017;62(3):170\u201381. https:\/\/doi.org\/10.1177\/0706743716673321.","journal-title":"Can J Psychiatry"},{"key":"1282_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2024.105237","author":"ECY Lau","year":"2024","unstructured":"Lau ECY, Chen W, Lu CY, Hilmer SN, Jeon Y-H, Tan ECK. Antidementia and psychotropic drug use in older people with dementia in australia: a national data linkage study. J Am Med Dir Assoc. 2024. https:\/\/doi.org\/10.1016\/j.jamda.2024.105237.","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"1282_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2040622316658463","volume":"7","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229\u201345. https:\/\/doi.org\/10.1177\/2040622316658463.","journal-title":"Ther Adv Chronic Dis"},{"issue":"9","key":"1282_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2025.105750","volume":"26","author":"HT Le","year":"2025","unstructured":"Le HT, Lau ECY, Ali MA, Lu CY, Hilmer SN, Jeon YH, et al. Potentially high-risk antipsychotic use in people with dementia: a national data linkage study. J Am Med Dir Assoc. 2025;26(9):105750. https:\/\/doi.org\/10.1016\/j.jamda.2025.105750.","journal-title":"J Am Med Dir Assoc"},{"key":"1282_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076268","volume":"385","author":"PLH Mok","year":"2024","unstructured":"Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385:e076268. https:\/\/doi.org\/10.1136\/bmj-2023-076268.","journal-title":"BMJ"},{"key":"1282_CR11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.10419","author":"J Choma","year":"2025","unstructured":"Choma J, Griffiths A, Henley W, Mueller C, Williams N, Ballard C, et al. Risk of stroke associated with risperidone in dementia with and without comorbid cardiovascular disease: population-based matched cohort study. Br J Psychiatry. 2025. https:\/\/doi.org\/10.1192\/bjp.2025.10419.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"1282_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40266-022-00992-5","volume":"40","author":"M Rogowska","year":"2023","unstructured":"Rogowska M, Thornton M, Creese B, Velayudhan L, Aarsland D, Ballard C, et al. Implications of adverse outcomes associated with antipsychotics in older patients with dementia: a 2011-2022 update. Drugs Aging. 2023;40(1):21\u201332. https:\/\/doi.org\/10.1007\/s40266-022-00992-5.","journal-title":"Drugs Aging"},{"issue":"3","key":"1282_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0828","volume":"2","author":"I Yunusa","year":"2019","unstructured":"Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019;2(3):e190828. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0828.","journal-title":"JAMA Netw Open"},{"issue":"23","key":"1282_CR14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1212\/wnl.0000000000207078","volume":"100","author":"AA Veroniki","year":"2023","unstructured":"Veroniki AA, Seitidis G, Tsivgoulis G, Katsanos AH, Mavridis D. An introduction to individual participant data meta-analysis. Neurology. 2023;100(23):1102\u201310. https:\/\/doi.org\/10.1212\/wnl.0000000000207078.","journal-title":"Neurology"},{"issue":"1","key":"1282_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02202-9","volume":"24","author":"F Bouvier","year":"2024","unstructured":"Bouvier F, Chaimani A, Peyrot E, Gueyffier F, Grenet G, Porcher R. Estimating individualized treatment effects using an individual participant data meta-analysis. BMC Med Res Methodol. 2024;24(1):74. https:\/\/doi.org\/10.1186\/s12874-024-02202-9.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"1282_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70665","volume":"21","author":"HT Le","year":"2025","unstructured":"Le HT, Lau ECY, Lu CY, Hilmer SN, Jeon YH, Low LF, et al. Treatment modifiers and predictors of risperidone response in dementia: an individual participant data meta-analysis of six randomized controlled trials. Alzheimers Dement. 2025;21(9):e70665. https:\/\/doi.org\/10.1002\/alz.70665.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1282_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/01.jcp.0000239796.21826.39","volume":"26","author":"M Haupt","year":"2006","unstructured":"Haupt M, Cruz-Jentoft A, Jeste D. Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol. 2006;26(6):566\u201370. https:\/\/doi.org\/10.1097\/01.jcp.0000239796.21826.39.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1282_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1192\/bjp.bp.115.177683","volume":"209","author":"R Howard","year":"2016","unstructured":"Howard R, Costafreda SG, Karcher K, Coppola D, Berlin JA, Hough D. Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. Br J Psychiatry. 2016;209(5):378\u201384. https:\/\/doi.org\/10.1192\/bjp.bp.115.177683.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"1282_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40266-025-01202-8","volume":"42","author":"TJD Tan","year":"2025","unstructured":"Tan TJD, Lau ECY, Le TH, Lu CY, Hilmer SN, Jeon YH, et al. Predictors and moderators of hospitalisation and mortality in people with dementia using antipsychotics: systematic review. Drugs Aging. 2025;42(5):381\u201394. https:\/\/doi.org\/10.1007\/s40266-025-01202-8.","journal-title":"Drugs Aging"},{"issue":"5","key":"1282_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMp1607342","volume":"375","author":"HM Krumholz","year":"2016","unstructured":"Krumholz HM, Waldstreicher J. The Yale Open Data Access (YODA) project: a mechanism for data sharing. N Engl J Med. 2016;375(5):403\u20135. https:\/\/doi.org\/10.1056\/NEJMp1607342.","journal-title":"N Engl J Med"},{"issue":"3","key":"1282_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/00019442-199911001-00147","volume":"8","author":"B Reisberg","year":"1996","unstructured":"Reisberg B, Auer SR, Monteiro IM. Behavioral pathology in Alzheimer\u2019s disease (BEHAVE-AD) rating scale. Int Psychogeriatr. 1996;8(3):301\u20138. https:\/\/doi.org\/10.1097\/00019442-199911001-00147.","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"1282_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01440-5","volume":"21","author":"E Bosco","year":"2021","unstructured":"Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21(1):241. https:\/\/doi.org\/10.1186\/s12874-021-01440-5.","journal-title":"BMC Med Res Methodol"},{"key":"1282_CR23","unstructured":"World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification. Available from: https:\/\/atcddd.fhi.no\/atc_ddd_index\/. Accessed 06 Aug 2025."},{"key":"1282_CR24","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20f13681","author":"C Andrade","year":"2020","unstructured":"Andrade C. Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry. 2020. https:\/\/doi.org\/10.4088\/JCP.20f13681.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1282_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10654-020-00643-2","volume":"36","author":"C Mueller","year":"2021","unstructured":"Mueller C, John C, Perera G, Aarsland D, Ballard C, Stewart R. Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. Eur J Epidemiol. 2021;36(1):89\u2013101. https:\/\/doi.org\/10.1007\/s10654-020-00643-2.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"1282_CR26","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.21037\/jtd.2017.05.34","volume":"9","author":"SY Chen","year":"2017","unstructured":"Chen SY, Feng Z, Yi X. A general introduction to adjustment for multiple comparisons. J Thorac Dis. 2017;9(6):1725\u20139. https:\/\/doi.org\/10.21037\/jtd.2017.05.34.","journal-title":"J Thorac Dis"},{"issue":"1","key":"1282_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1\u201348. https:\/\/doi.org\/10.18637\/jss.v067.i01.","journal-title":"J Stat Softw"},{"key":"1282_CR28","unstructured":"Terry M. Therneau. coxme: mixed effects Cox models. 2024. Available from: https:\/\/CRAN.R-project.org\/package=coxme. Accessed 31 Dec 2025."},{"issue":"6","key":"1282_CR29","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/hec.4510","volume":"31","author":"A Gabrio","year":"2022","unstructured":"Gabrio A, Plumpton C, Banerjee S, Leurent B. Linear mixed models to handle missing at random data in trial-based economic evaluations. Health Econ. 2022;31(6):1276\u201387. https:\/\/doi.org\/10.1002\/hec.4510.","journal-title":"Health Econ"},{"issue":"12","key":"1282_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013304.pub2","volume":"12","author":"V M\u00fchlbauer","year":"2021","unstructured":"M\u00fchlbauer V, M\u00f6hler R, Dichter MN, Zuidema SU, K\u00f6pke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12(12):Cd013304. https:\/\/doi.org\/10.1002\/14651858.CD013304.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1282_CR31","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/jgs.17623","volume":"70","author":"A N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard A, Jensen-Dahm C, Wimberley T, Svendsen JH, Ishtiak-Ahmed K, Laursen TM, et al. Effect of antipsychotics on mortality risk in patients with dementia with and without comorbidities. J Am Geriatr Soc. 2022;70(4):1169\u201379. https:\/\/doi.org\/10.1111\/jgs.17623.","journal-title":"J Am Geriatr Soc"},{"issue":"7497","key":"1282_CR32","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/bmj.330.7497.922-c","volume":"330","author":"J Lenzer","year":"2005","unstructured":"Lenzer J. FDA warns about using antipsychotic drugs for dementia. BMJ. 2005;330(7497):922. https:\/\/doi.org\/10.1136\/bmj.330.7497.922-c.","journal-title":"BMJ"},{"issue":"8","key":"1282_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1756285617712979","volume":"10","author":"OP Tible","year":"2017","unstructured":"Tible OP, Riese F, Savaskan E, von Gunten A. Best practice in the management of behavioural and psychological symptoms of dementia. Ther Adv Neurol Disord. 2017;10(8):297\u2013309. https:\/\/doi.org\/10.1177\/1756285617712979.","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"1282_CR34","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00702-021-02369-1","volume":"128","author":"J Seifert","year":"2021","unstructured":"Seifert J, Letmaier M, Greiner T, Schneider M, Deest M, Eberlein CK, et al. Psychotropic drug-induced hyponatremia: results from a drug surveillance program-an update. J Neural Transm (Vienna). 2021;128(8):1249\u201364. https:\/\/doi.org\/10.1007\/s00702-021-02369-1.","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"1282_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1539-0","volume":"17","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017;17(1):373. https:\/\/doi.org\/10.1186\/s12888-017-1539-0.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1282_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12779\/dnd.2016.15.1.1","volume":"15","author":"JG Jeong","year":"2016","unstructured":"Jeong JG, Song JA, Park KW. A relationship between depression and wandering in community-dwelling elders with dementia. Dement Neurocogn Disord. 2016;15(1):1\u20136. https:\/\/doi.org\/10.12779\/dnd.2016.15.1.1.","journal-title":"Dement Neurocogn Disord"},{"issue":"4","key":"1282_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/jamapsychiatry.2019.3993","volume":"77","author":"AJ Fett","year":"2020","unstructured":"Fett AJ, Velthorst E, Reichenberg A, Ruggero CJ, Callahan JL, Fochtmann LJ, et al. Long-term changes in cognitive functioning in individuals with psychotic disorders: findings from the suffolk county mental health project. JAMA Psychiat. 2020;77(4):387\u201396. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.3993.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"1282_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","volume":"173","author":"VI Reus","year":"2016","unstructured":"Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American psychiatric association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543\u20136. https:\/\/doi.org\/10.1176\/appi.ajp.2015.173501.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1282_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5049\/ebp.2015.13.1.17","volume":"13","author":"SW Oh","year":"2015","unstructured":"Oh SW, Han SY. Loop diuretics in clinical practice. Electrolyte Blood Press. 2015;13(1):17\u201321. https:\/\/doi.org\/10.5049\/ebp.2015.13.1.17.","journal-title":"Electrolyte Blood Press"},{"key":"1282_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2021.110654","volume":"151","author":"A Pinkhasov","year":"2021","unstructured":"Pinkhasov A, Xiong G, Bourgeois JA, Heinrich TW, Huang H, Coriolan S, et al. Management of SIADH-related hyponatremia due to psychotropic medications\u2014an expert consensus from the Association of Medicine and Psychiatry. J Psychosom Res. 2021;151:110654. https:\/\/doi.org\/10.1016\/j.jpsychores.2021.110654.","journal-title":"J Psychosom Res"},{"issue":"3","key":"1282_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jtho.2020.12.008","volume":"16","author":"X Wang","year":"2021","unstructured":"Wang X, Piantadosi S, Le-Rademacher J, Mandrekar SJ. Statistical considerations for subgroup analyses. J Thorac Oncol. 2021;16(3):375\u201380. https:\/\/doi.org\/10.1016\/j.jtho.2020.12.008.","journal-title":"J Thorac Oncol"},{"key":"1282_CR42","unstructured":"National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their careers. London: National Institute for Health and Care Excellence (NICE); 2018. Available from: https:\/\/www.nice.org.uk\/guidance\/ng97\/resources\/dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109. Accessed 31 Dec 2025."},{"key":"1282_CR43","unstructured":"Bell S, Bhat R, Brennan S, Clark M, Corlis M, Etherton B. Clinical practice guidelines for the appropriate use of psychotropic medications in people living with dementia and in residential aged care: summary of recommendations and good practice statements. Parkville: Monash University; 2022. Available from: https:\/\/www.monash.edu\/__data\/assets\/pdf_file\/0005\/3657128\/240424_Clinical-Pracitcie-Guidelines-for-the-Appropriate-Use-of-Psychotorpic-Medications-in-People-Living-with-Dementia-and-in-Residential-Aged-Care.pdf. Accessed 31 Dec 2025."},{"issue":"10","key":"1282_CR44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S2215-0366(25)00261-5","volume":"12","author":"HC Smith","year":"2025","unstructured":"Smith HC, Petersen I, Hayes JF, Jordan KP, Boman M, Banerjee S, et al. Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines. Lancet Psychiatry. 2025;12(10):758\u201367. https:\/\/doi.org\/10.1016\/S2215-0366(25)00261-5.","journal-title":"Lancet Psychiatry"},{"key":"1282_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.schres.2024.12.018","volume":"275","author":"EY Kim","year":"2025","unstructured":"Kim EY, Kim J, Jeong JH, Jang J, Kang N, Seo J, et al. Machine learning prediction model of the treatment response in schizophrenia reveals the importance of metabolic and subjective characteristics. Schizophr Res. 2025;275:146\u201355. https:\/\/doi.org\/10.1016\/j.schres.2024.12.018.","journal-title":"Schizophr Res"},{"issue":"1","key":"1282_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1406-z","volume":"17","author":"C Henshall","year":"2017","unstructured":"Henshall C, Marzano L, Smith K, Attenburrow M-J, Puntis S, Zlodre J, et al. A web-based clinical decision tool to support treatment decision-making in psychiatry: a pilot focus group study with clinicians, patients and carers. BMC Psychiatry. 2017;17(1):265. https:\/\/doi.org\/10.1186\/s12888-017-1406-z.","journal-title":"BMC Psychiatry"},{"key":"1282_CR47","doi-asserted-by":"publisher","DOI":"10.1177\/14713012251366757","volume":"2025","author":"TJD Tan","year":"2025","unstructured":"Tan TJD, Jeon YH, Lau ECY, Hilmer SN, Low LF, Lu CY, et al. Developing a novel digital tool for personalised antipsychotic prescribing in people living with dementia: the views of Australian clinicians. Dementia (London). 2025;2025:14713012251366757. https:\/\/doi.org\/10.1177\/14713012251366757.","journal-title":"Dementia (London)"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01282-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01282-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01282-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:29:24Z","timestamp":1776698964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01282-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01282-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the University of Sydney Human Research Ethics Committee (approval no. 2024\/HE000171).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Data in this study are available through the Yale University Open Data Access Project.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statements"}},{"value":"Conceptualisation: ET, SH, YJ, CL, LL. Methodology: ET, HL, EL. Formal analysis and investigation: HL, EL. Writing\u2014original draft preparation: HL. Writing\u2014review and editing: ET, SH, YJ, CL, LL, TN. Funding acquisition: ET. Supervision: ET. All authors have read and approved the final version of the manuscript and agreed to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}